Esco Lifesciences Raises $200 Million in Series A Funding Round

(VCBeat) May. 27, 2021 -- Esco Lifesciences (NASDAQ: ESCO) today announced the closing of a $200 million oversubscribed Series A funding round, led by Vivo Capital and Novo Holdings A/S, with participation from high-profile investors, including China Investment Corporation, Singapore-based global investor EDBI, a reputable, long-term institutional investor, and others.

Esco Lifesciences provides supporting technologies, products and services for academic research and scientific research, clinical trials, and the development and manufacturing of biopharmaceuticals in the life sciences and healthcare industries.

Headquartered in Singapore, Esco Lifesciences has an extensive sales network in more than 100 countries, sales and service branches in more than 20 countries, and eight manufacturing and research and development centers in the United States, Europe, the United Kingdom, China, Singapore, and Indonesia, employing more than 1,300 people worldwide.

As a leading provider of life science tools and services, Esco Lifesciences is poised to benefit from the continued growth of the healthcare and biopharmaceutical industries in Asia and globally. Esco Lifesciences has achieved market leadership in several categories in some of its fastest-growing market segments, both in China and globally. China is also its largest and fastest-growing market. With its headquarter located in Singapore, Esco Group is an important hub of China's investment in countries along the "One Belt And One Road" route, as well as a nexus of economic, cultural and scientific exchanges between the East and the West. While building a bridge of science and technology, innovative products and high-end talents on a global scale, Esco Group will grasp the opportunity of China's dual-cycle strategy and expand the global business across the United States, Europe and Asia.

Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high-quality companies. Since its inception, the firm has raised over $5.8 billion in capital and backed over 300 private and public portfolio companies. Vivo Capital is headquartered in Palo Alto, California, with offices in Beijing, Shanghai, Hong Kong, and Taipei.

Vivo Capital is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.

Novo Holdings is recognized as a leading life science investor with a focus on creating long-term value. As a life sciences investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.